India’s Tata Institute develops tablet for cancer recurrence prevention
29 Feb 2024
Preview
Source: Pharmaceutical Technology
The pro-oxidant tablet has shown a 30% effectiveness in preventing cancer. White Bear studio / Shutterstock.com.
India’s Tata Institute of Fundamental Research (TIFR) has announced the development of a new pro-oxidant tablet, combining resveratrol and copper (R+Cu), that has the potential to prevent the recurrence of cancer.
More than a decade of research at the Tata Memorial Centre has resulted in the creation of this tablet which will be priced at around Rs100 ($1.2), Indian media publication NDTV has reported.
The R+Cu tablet, when ingested, produces oxygen radicals within the stomach.
These radicals are rapidly absorbed into the bloodstream, where they target and destroy cfChPs, hindering the process of metastasis—the spread of cancer cells to other body parts.
See Also:EMA awards double validation for Daiichi Sankyo and AstraZeneca’s cancer ADC
Preview
Source: Pharmaceutical Technology
Memorial Sloan Kettering Cancer Center in artificial intelligence: theme innovation strategy
Preview
Source: Pharmaceutical Technology
The tablet also reduces the toxicity associated with chemotherapy and diminishes the overall side effects of cancer treatment by around 50%.
It has shown 30% effectiveness in preventing cancer.
Its potential extends to the treatment of cancers including pancreatic, oral and lung.
Tata Memorial Hospital senior cancer surgeon Dr Rajendra Badve stated: “Tata doctors were working on this tablet for almost a decade.
“The tablet is awaiting approval from the Food Safety and Standards Authority of India (FSSAI). TIFR scientists have applied to FSSAI to approve this tablet.
“This tablet will be available everywhere for just Rs100.”
The institute plans to make the tablet available from June/July 2024 for cancer patients following approval from the Indian regulator.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Drugs
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.